Aleva Neurotherapeutics Closes EUR 9.5 Million Series A Financing Round
Lausanne, Switzerland, August 25, 2011 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series A financing round totaling EUR 9.5 million. Aleva was founded in 2008 as a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) Microsystems Laboratory.
The round was funded by a group of seasoned industry specialists and co-led by BioMedInvest AG (managed by BioMedPartners AG, Basel, Switzerland) and BB BIOTECH VENTURES III, L.P. (advised by Bellevue Asset Management AG, Kuesnacht, Switzerland). Initiative Capital Romandie (Lausanne, Switzerland) and renowned private investors also participated in the financing.
The proceeds will be used to support the development of Aleva’s pioneering product pipeline for neurostimulation, which is based on the company’s proprietary microDBS™ technology. microDBS™ is a next-generation technology addressing Deep Brain Stimulation therapy, currently a US$ 450 million market with strong double-digit growth rates.
Aleva’s microDBS™ technology for target-specific stimulation has been developed to significantly reduce the side effects and potential complications as well as the costs of DBS therapy. Moreover, its features allow for expanding the existing DBS market to new indications which cannot be addressed by currently available technologies.
The company is developing three products based on its microDBS™ technology: directSTIM™, an intelligent electrode compatible with existing DBS platforms; spiderSTIM™, a full solution for both intra-surgical and long-term therapeutic use; and the cortiSTIM™ device for cortical stimulation.
All products will be compatible with marketed pulse generators. Clinical trials of the lead product, directSTIM™, are scheduled to start later this year.
“The combination of Aleva Neurotherapeutics’ technology, pipeline and management team has convinced us that the company is in an excellent position to significantly improve the treatment options for patients with Parkinson´s disease, depression and other important neurological disease indications. Building its innovative technology on a proven treatment mechanism called Deep Brain Stimulation, Aleva has chosen a fast route to market, which will hopefully allow both physicians and patients to benefit from novel neurostimulation devices in the very near future,” said Markus Hosang, General Partner at BioMedPartners AG.
“Since its inception in 2008, Aleva has demonstrated that it is a product-driven company with a sound business strategy. The first product, which is supported by an attractive follow-on pipeline, is already approaching clinical trials,” said Juerg Eckhardt, Investment Advisor to BB BIOTECH VENTURES. “Its leading-edge technology has the potential to add substantial benefits to existing DBS platforms and to expand this therapy to additional indications. We therefore are convinced that the company and its products will be met with great interest by physicians, patients and potential corporate partners.”
“We are very pleased to have attracted such a highly experienced group of investors,” added Jean-Pierre Rosat, CEO of Aleva Neurotherapeutics. “The funding enables us to speed up the development of our pipeline and to intensify our partnering efforts. Moreover, we have established a strong Board of Directors, which will be of tremendous value for implementing our business strategy of bringing next-generation neurostimulation products to market, which are synergistic with existing approaches.”
Aleva’s Board of Directors is chaired by Oern Stuge, MD, who has a long-standing management track record with Medtronic Inc. and Abbott Laboratories Inc., among others. Other members of the Board are André Mercanzini, CTO and co-founder of Aleva, Markus Hosang of Biomedinvest AG and Juerg Eckhardt of Bellevue Asset Management AG. Moreover, Paul LaViolette, Partner at SV Life Sciences and formerly COO of Boston Scientific, and Andres Lozano, Professor of Neurosurgery at the Toronto Western Hospital will act as advisors to the company.
“The growing patient population with severe neurological disorders fuels the need for novel, optimized products that can make brain stimulation even more effective, lower its side effects and help more patients to a better life,” said Oern Stuge, Chairman of Aleva’s Board of Directors. “Aleva’s microDBS™ technology allows for smaller, much more versatile electrodes to be used for targeted neurostimulation. I believe that this is a highly attractive value proposition for physicians who are already using approved DBS systems and are looking for next-generation add-ons to the existing therapy.”
About Aleva Neurotherapeutics:
Aleva Neurotherapeutics develops next-generation neurostimulation technologies and devices for Deep Brain Stimulation (DBS) therapy. Its solutions are designed to be more versatile, more precise and more efficient than currently available DBS approaches while causing fewer side effects and complications. Based on its proprietary microDBS™ technology, Aleva develops three novel, brain stimulating products with different properties. The first, called directSTIM™, is an intelligent electrode compatible with existing DBS systems; the second, called spiderSTIM™, is a full solution for both intra-surgical and long-term therapeutic use; and the third named cortiSTIM™ is a device for cortical stimulation. All of Aleva’s products are fully compatible with existing DBS technologies and devices.
The company is a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL) Microsystems Laboratory of Prof. Philippe Renaud. In August 2011, Aleva Neurotherapeutics raised a Series A round of financing totaling EUR 9.5 million from a group of renowned investors, among them BioMedInvest AG, BB Biotech Ventures LP, Initiative Capital Romandie and selected private investors.
Aleva Neurotherapeutics SA
PSE-D, EPFL Campus
+41-21-693 87 64
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aleva Neurotherapeutics Closes EUR 9.5 Million Series A Financing Round here
News-ID: 189172 • Views: 3280
More Releases from Aleva Neurotherapeutics
Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round
- Lead investor Banexi Ventures Partners joins strong investment consortium - Lausanne, Switzerland, April 10, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the closing of a Series B financing round totaling CHF 4.0 million. Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating in
Aleva Neurotherapeutics Expands Board of Directors
- Entrepreneur Martin Velasco and Industry Expert Scott R. Ward Appointed as Board Members - Lausanne, Switzerland, March 20, 2012 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced the expansion of its Board of Directors. Martin Velasco, a seasoned entrepreneur and business angel, and Scott R. Ward, advisor and former Senior Vice President and
More Releases for DBS
DBS Wealth Management Market 2019: Business Planning Research Analysis by DBS, …
DBS Group is a financial services company with a presence in 18 markets. It has four main business segments and offers wealth management services through its Consumer Banking/Wealth Management (CBWM) unit. The wealth business is further divided into three tiered propositions, with a focus on Asia. Get Sample Copy of This Report at@ https://www.orbisresearch.com/contacts/request-sample/2663614 This competitor profile provides a comprehensive analysis of DBS's wealth operations. It offers insight into the company’s strategy
DBS Bank: Key Strategies and Innovations to Witness Growth
DBS appointed Neal Cross as chief innovation officer. He is responsible for driving the banks digital innovation agenda across Asia. The bank has also partnered with various government-backed venture capital firms, non-profit organizations, and technology providers to help its SME and other corporate customers find digital solutions as per their business needs. Such factors that have been influencing growth of DBS bank have been included in a report titled “DBS
DBS Bank Fintech Ecosystem Market Innovation Initiatives and Strategy by Carouse …
In 2014, DBS appointed Neal Cross as chief innovation officer. He is responsible for driving the bank’s digital innovation agenda across Asia. In the same year, DBS committed S$200m to build a digital infrastructure for the bank, leveraging big data, biometrics, and artificial intelligence (AI) technologies. DBS Bank established a developer team to create APIs and launch the world’s largest API platform. The bank has also partnered with various government-backed venture
FinTrack Market Is Booming Worldwide| Paytm, SkyWatch, Barclays, DBS Bank
HTF Market Intelligence released a new research report of 19 pages on title 'FinTrack Market 2018’ with detailed analysis, forecast and strategies. The study covers key regions that includes North America, Europe or Asia and important players such as Stripe, AgeWage, Barclays, Umpqua Bank, DBS Bank, Aberdeen Standard Investments, Paytm, SkyWatch, Homelyfe Request a sample report @ https://www.htfmarketreport.com/sample-report/1399361-fintrack-september-2018 Summary Every month, FinTrack will showcase the latest innovations from financial providers around the
Deep Brain Stimulation Devices Market Analysis On the basis of Products such as …
Deep Brain Stimulation is a neosurgical system which treats an assortment of devastating neurological responses. It joins the implantation of a battery-worked restorative gadget called Neurostimulator. Neurostimulation development can improve the life idea of the people who are truly stifled or encountering critical mishaps to various sense organs, and also to last decline of outrageous, unending torment which would somehow require unfaltering (day and night), high-measurements opioid treatment, (for instance,
DBS Central’s Optimised DBS Check Systems Deliver 1-Hour Processing
London, United Kingdom, Tuesday, August 30th, 2016 The DBS Central agency’s streamlined online platform has formally announced that it is capable of delivering DBS check processing times of just one hour. Today, DBS Central, a leading Disclosure and Barring Service, DBS provider in the United Kingdom for individuals and companies, has confirmed that its faster and more user-friendly online portal has tracked an impressive processing turnaround time of just one hour. From the